BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 140,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 8th. The stock was sold at an average price of $82.67, for a total transaction of $11,573,800.00. Following the sale, the chief executive officer now owns 393,368 shares of the company’s stock, valued at $32,519,732.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Jean Jacques Bienaime also recently made the following trade(s):

  • On Monday, November 7th, Jean Jacques Bienaime sold 70,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $82.52, for a total transaction of $5,776,400.00.
  • On Friday, October 28th, Jean Jacques Bienaime sold 120,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $81.30, for a total transaction of $9,756,000.00.
  • On Monday, October 17th, Jean Jacques Bienaime sold 41,666 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $84.39, for a total transaction of $3,516,193.74.
  • On Friday, October 14th, Jean Jacques Bienaime sold 64,125 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $86.96, for a total transaction of $5,576,310.00.
  • On Thursday, September 29th, Jean Jacques Bienaime sold 53,125 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $93.65, for a total transaction of $4,975,156.25.
  • On Friday, September 16th, Jean Jacques Bienaime sold 137,368 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $95.34, for a total transaction of $13,096,665.12.
  • On Tuesday, August 16th, Jean Jacques Bienaime sold 41,666 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $91.49, for a total transaction of $3,812,022.34.

Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) opened at 91.46 on Monday. The firm’s market capitalization is $15.73 billion. The firm has a 50-day moving average of $87.93 and a 200 day moving average of $89.19. BioMarin Pharmaceutical Inc. has a 52-week low of $62.12 and a 52-week high of $110.35.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings results on Thursday, October 27th. The company reported ($0.26) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.39) by $0.13. The company earned $279.90 million during the quarter, compared to analysts’ expectations of $289.70 million. BioMarin Pharmaceutical had a negative net margin of 46.22% and a negative return on equity of 8.54%. The business’s quarterly revenue was up 34.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.60) earnings per share. Analysts predict that BioMarin Pharmaceutical Inc. will post ($3.73) EPS for the current year.

Insider Buying and Selling by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

A number of analysts recently weighed in on BMRN shares. William Blair set a $116.00 target price on shares of BioMarin Pharmaceutical and gave the stock a “buy” rating in a report on Thursday, July 28th. Jefferies Group set a $116.00 price target on shares of BioMarin Pharmaceutical and gave the company a “buy” rating in a research report on Thursday, July 28th. Credit Suisse Group AG set a $111.00 price target on shares of BioMarin Pharmaceutical and gave the company a “buy” rating in a research report on Thursday, July 28th. Cowen and Company restated a “buy” rating on shares of BioMarin Pharmaceutical in a research report on Thursday, July 28th. Finally, Zacks Investment Research upgraded shares of BioMarin Pharmaceutical from a “hold” rating to a “buy” rating and set a $104.00 price target for the company in a research report on Tuesday, July 19th. Six analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $115.11.

Several hedge funds have recently made changes to their positions in BMRN. Pacer Advisors Inc. raised its stake in shares of BioMarin Pharmaceutical by 1.2% in the second quarter. Pacer Advisors Inc. now owns 4,339 shares of the company’s stock worth $338,000 after buying an additional 52 shares in the last quarter. CIBC Asset Management Inc raised its stake in shares of BioMarin Pharmaceutical by 0.5% in the third quarter. CIBC Asset Management Inc now owns 11,723 shares of the company’s stock worth $1,085,000 after buying an additional 56 shares in the last quarter. Hartford Investment Management Co. raised its stake in shares of BioMarin Pharmaceutical by 2.5% in the second quarter. Hartford Investment Management Co. now owns 2,906 shares of the company’s stock worth $226,000 after buying an additional 70 shares in the last quarter. Mn Services Vermogensbeheer B.V. raised its stake in shares of BioMarin Pharmaceutical by 1.9% in the third quarter. Mn Services Vermogensbeheer B.V. now owns 4,161 shares of the company’s stock worth $385,000 after buying an additional 79 shares in the last quarter. Finally, Essex Investment Management Co. LLC raised its stake in shares of BioMarin Pharmaceutical by 0.6% in the second quarter. Essex Investment Management Co. LLC now owns 15,411 shares of the company’s stock worth $1,199,000 after buying an additional 90 shares in the last quarter. 93.59% of the stock is currently owned by institutional investors and hedge funds.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc (BioMarin) develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company’s product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. Its approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate).

5 Day Chart for NASDAQ:BMRN

Receive News & Stock Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.